PRA Health Sciences, Inc. Reports Second Quarter 2020 Results and Provides Third Quarter and Full Year 2020 Guidance
(WorldNews Europe)

PDF Version Net new business of $701.6 million; Net book-to-bill of 1.35 excluding reimbursement revenue Net new business of $1,083.3 million; Net book-to-bill of 1.62 including reimbursement revenue $729.9 million of total revenue; representing a decrease of 4.4% at actual foreign exchange rates and 3.8% on a constant currency basis GAAP net income per diluted share of $0.22; GAAP net income of $13.9 million Adjusted net income per diluted share was $0.86; Adjusted net income of $55.2 million Full year 2020 revenue guidance between $3.07 billion and $3.13 billion, GAAP net income per diluted share between $2.40 and $2.60 and adjusted net income per diluted share between $4.35 and $4.55...